Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Genitourinary tumours, non-prostate 1

LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Date

17 Sep 2021

Session

Proffered Paper session - Genitourinary tumours, non-prostate 1

Presenters

Thomas Powles

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

T.B. Powles1, V. Chistyakov2, V. Beliakouski3, A. Semenov4, E. Everaert5, Y. Baranau6, V. Moreno7, B. Perez Valderrama8, Y. Vano9, G. Del Conte10, Y. Loriot11, T.W. Kang12, M. Tammaro13, A. O'Hagan13, M. Hosseini13, S. Triantos13, H. Chhabra13, A. Santiago-Walker13, A.O. Siefker-Radtke14

Author affiliations

  • 1 Department Of Genitourinary Oncology, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 2 Medical Oncology, LLC Novaya Clinica, 357500 - Pyatigorsk/RU
  • 3 Medical Oncology, Gomel Regional Clinical Oncology Dispensary, 246041 - Gomel/RU
  • 4 Ivanovo Regional Oncology Dispensary, Regional Budgetary Healthcare Institution, 153040 - Ivanovo/RU
  • 5 Medical Oncology, AZ Nikolaas Hospital, 9100 - St Niklaas/BE
  • 6 Chemotherapy Department, Minsk City Clinical Cancer Center, 220089 - Minsk/BY
  • 7 Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz, University Hospital, 08908 - Madrid/ES
  • 8 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Seville/ES
  • 9 Medical Oncology, Université Paris Descartes Sorbonne Paris Cité, INSERM UMRS970, 75015 - Paris/FR
  • 10 Department Of Oncology, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT
  • 11 Medical Oncology, Institut Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, 94805 - Villejuif/FR
  • 12 Urology, Chonnam National University Medical School, 160 - Gwangju/KR
  • 13 Research & Development, Janssen Research & Development, 19002 - Spring House/US
  • 14 Genitourinary Medical Oncology Department, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA27

Background

First-line (1L) therapy for cisplatin (cis)-ineligible patients (pts) with mUC includes alternative chemotherapy or anti-PD-(L)1 monotherapy for PD-L1 positive tumors. The pan-FGFR inhibitor ERDA has established clinical benefit in 2L mUC for pts with targetable FGFRa. ERDA combined with the anti-PD-1 CET could expand 1L options for pts with FGFRa. The Ph 1b part of NORSE (NCT03473743) determined a tolerable dose of ERDA + CET in pts with 2L mUC. We report early results from the Ph 2 part of NORSE evaluating ERDA or ERDA + CET in cis-ineligible pts with 1L mUC and FGFRa.

Methods

NORSE Ph 2 is enrolling pts ≥ 18 y with mUC, select FGFRa (mutation/fusion), and measurable disease (no prior systemic therapy for mUC, cis ineligible). Pts are randomized 1:1 to receive once-daily ERDA 8 mg (with pharmacodynamically guided uptitration [UpT] to 9 mg) or ERDA 8 mg (no UpT) + IV CET 240 mg every 2 wks at cycles 1-4 and 480 mg every 4 wks thereafter. Primary end points are investigator-assessed overall response rate (ORR) per RECIST 1.1 and safety; secondary include disease control rate (DCR), time to response (TTR), and duration of response (DOR).

Results

As of July 19, 2021, 53 pts were randomized; 26 to ERDA and 27 to ERDA + CET. For ERDA vs ERDA + CET: median age was 75 vs 69 y; visceral metastases were present in 54% vs 52%; ECOG was 0-1 in 77% vs 63%. Efficacy data in response-evaluable pts are shown in the table. The safety set comprised 24 pts who received ERDA and 24 who received ERDA + CET. The most frequent treatment-emergent adverse events were hyperphosphatemia (ERDA vs ERDA + CET, 58% vs 58%), stomatitis (63% vs 54%), and diarrhea (50% vs 42%). Table: LBA27

Efficacy in response evaluable pts

ERDA 8 mg with UpT (n = 18) ERDA 8 mg + CET (n = 19)
ORR, % (95% CI) 33 (13-59) 68 (43-87)
Confirmed CR, n 1 4
DCR, % (95% CI) 100 (82-100) 90 (67-99)
Median DOR (95% CI), mo NE (4.4-NE) 6.9 (1.6-NE)
Confirmed response ongoing, n/N 5/6 10/13
Median TTR, mo 2.3 1.8

Conclusions

ERDA + CET showed clinically meaningful responses in cis-ineligible patients with 1L mUC and FGFRa. Safety was generally consistent with ERDA alone. Enrollment is ongoing.

Clinical trial identification

NCT03473743.

Editorial acknowledgement

Medical writing assistance was provided by Benjamin Ricca, PhD, Autumn Kelly, MA, and Khalida Rizi, MPharm, PhD, of Parexel, and was funded by Janssen Global Services, LLC.

Legal entity responsible for the study

Janssen Research & Development, LLC.

Funding

Janssen Research & Development, LLC.

Disclosure

T.B. Powles: Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Other, Honoraria/Consultant fees: Astellas; Financial Interests, Personal, Other, Honoraria/Consultant fees: AstraZeneca; Financial Interests, Personal, Other, Honoraria/Consultant fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria/Consultant fees: Eisai; Financial Interests, Personal, Other, Honoraria/Consultant fees: Exelixis; Financial Interests, Personal, Other, Honoraria/Consultant fees: F. Hoffmann-La Roche; Financial Interests, Personal, Other, Honoraria/Consultant fees: Johnson & Johnson; Financial Interests, Personal, Other, Honoraria/Consultant fees: Incyte; Financial Interests, Personal, Other, Honoraria/Consultant fees: Ipsen; Financial Interests, Personal, Other, Honoraria/Consultant fees: Merck; Financial Interests, Personal, Other, Honoraria/Consultant fees: Pfizer; Financial Interests, Personal, Other, Honoraria/Consultant fees: Seattle Genomics; Financial Interests, Personal, Other, Travel reimbursement: AstraZeneca; Financial Interests, Personal, Other, Travel reimbursement: F. Hoffmann-La Roche; Financial Interests, Personal, Other, Travel reimbursement: Ipsen; Financial Interests, Personal, Other, Travel reimbursement: Pfizer; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant: EMD Serono; Financial Interests, Institutional, Research Grant: Exelixis; Financial Interests, Institutional, Research Grant: F. Hoffmann-La Roche; Financial Interests, Institutional, Research Grant: Johnson & Johnson; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer. V. Moreno: Financial Interests, Personal, Advisory Role: Bayer, Bristol Myers Squibb. Y. Vano: Financial Interests, Personal, Advisory Role: BMS, MSD, Pfizer, Novartis, Ipsen, Roche, Astellas, Sanofi, Janssen. Y. Loriot: Financial Interests, Personal, Advisory Role: Janssen, Astellas Pharma, Roche, AstraZeneca, MSD Oncology, Clovis Oncology, Seattle Genetics, Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role: Janssen, MSD Oncology; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Astellas, Pharma, Janssen Oncology, Roche, AstraZeneca, MSD Oncology, Clovis Oncology, Seattle Genetics, Bristol Myers Squibb; Financial Interests, Personal, Other, Honorria: Sanofi, Pfizer; Financial Interests, Institutional, Funding: Sanofi, Jnssen Oncology, MSD Oncolofy, AstraZeneca, Clovis oncology, Exelixis, Boehringer Ingelheim, Incyte, Pfizer, Oncogenex, Medivation, CureVac, Nektar. T.W. Kang: Financial Interests, Personal, Full or part-time Employment: Chonnam National University Medical School, Chonnam National University Hospital; Financial Interests, Personal, Advisory Role: Janssen Pharmaceuticals, Astellas Pharma; Financial Interests, Personal, Research Grant: Alvogen Korea. M. Tammaro: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals. A. O'Hagan: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals . M. Hosseini: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals. S. Triantos: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals. H. Chhabra: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals. A. Santiago-Walker: Financial Interests, Personal, Full or part-time Employment: Janssen Pharmaceuticals. A.O. Siefker-Radtke: Financial Interests, Personal, Advisory Role: Janssen, Merck, NCCN, Bristol Myers Squibb, AstraZeneca, Bavarian Ndic, Seattle Genetics, Nektar, Genentech, EMD Serono, Mirati Therapeutics, Basilea; Financial Interests, Personal, Other, Patents, Royalties, Other Intellectual Property: Methods of Characterizing and treatng molecular subsets of Muscle-Invsive Bladder Cancer; Financial Interests, Personal, Funding: NH, Michael and Sherry Sutton Fund for Urothelial Cancer, Janssen, Takeda, Bristol Myers Squibb, BioClin Therapeutics, Nektar, Merck Sharp & Dohme, Basilea. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.